Published in Lancet Infect Dis on May 30, 2012
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature (2012) 3.83
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94
Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development. Proc Natl Acad Sci U S A (2014) 1.39
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest (2014) 1.18
Role of Fc-mediated antibody function in protective immunity against HIV-1. Immunology (2014) 1.09
Immunology. Immune activation with HIV vaccines. Science (2014) 1.07
Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines. Clin Vaccine Immunol (2014) 1.06
Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates. Vaccines (Basel) (2014) 1.04
Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS (2013) 1.01
Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward. AIDS Patient Care STDS (2015) 0.99
Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. J Virol (2014) 0.98
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis (2014) 0.98
Can immunological principles and cross-disciplinary science illuminate the path to vaccines for HIV and other global health challenges? Philos Trans R Soc Lond B Biol Sci (2015) 0.95
Progress in HIV-1 vaccine development. J Allergy Clin Immunol (2014) 0.94
A critical question for HIV vaccine development: which antibodies to induce? Science (2014) 0.91
Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial. J Virol (2013) 0.91
Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection. Hum Vaccin Immunother (2015) 0.91
Novel HIV vaccine strategies: overview and perspective. Ther Adv Vaccines (2013) 0.90
Preparing for the unexpected: the pivotal role of social and behavioral sciences in trials of biomedical HIV prevention interventions. J Acquir Immune Defic Syndr (2013) 0.90
HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials. AIDS Res Hum Retroviruses (2015) 0.87
Modulating the durability of anti-HIV gp120 antibody responses after vaccination: a comment on Wilson & Karp (2015). Philos Trans R Soc Lond B Biol Sci (2015) 0.85
Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users. Open Forum Infect Dis (2014) 0.84
Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines. Retrovirology (2012) 0.81
HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. Sci Transl Med (2015) 0.81
HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development. Curr HIV Res (2013) 0.80
A New Scientific Paradigm may be Needed to Finally Develop an HIV Vaccine. Front Immunol (2015) 0.80
Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. PLoS One (2016) 0.80
Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination. Clin Vaccine Immunol (2015) 0.80
High-Resolution Longitudinal Study of HIV-1 Env Vaccine-Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence. J Immunol (2016) 0.79
Human immunodeficiency virus vaccines. Infect Dis Clin North Am (2014) 0.79
Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus. World J Virol (2015) 0.79
A discrete-time survival model with random effects for designing and analyzing repeated low-dose challenge experiments. Biostatistics (2014) 0.79
Will HIV vaccination reshape HIV risk behavior networks? A social network analysis of drug users' anticipated risk compensation. PLoS One (2014) 0.78
Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. J Virol (2016) 0.78
Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. Curr Opin Virol (2016) 0.78
Modulation of HIV-1 immunity by adjuvants. Curr Opin HIV AIDS (2014) 0.78
Recent developments in clinical trial designs for HIV vaccine research. Hum Vaccin Immunother (2015) 0.77
Humoral Dysregulation Associated with Increased Systemic Inflammation among Injection Heroin Users. PLoS One (2016) 0.77
An HIV Vaccine for South-East Asia-Opportunities and Challenges. Vaccines (Basel) (2013) 0.77
Current views on the potential for development of a HIV vaccine. Expert Opin Biol Ther (2017) 0.77
Expectation of volunteers towards the vaccine efficacy of the prime-boost HIV vaccine phase III trial during unblinding. AIDS Res Hum Retroviruses (2014) 0.76
IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens. AIDS Res Hum Retroviruses (2015) 0.76
Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa. PLoS One (2016) 0.76
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog (2017) 0.76
Complex immune correlates of protection in HIV-1 vaccine efficacy trials. Immunol Rev (2017) 0.76
Understanding the efficacy variables of an HIV vaccine trial. Lancet Infect Dis (2012) 0.76
Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy. PLoS One (2016) 0.76
Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. Immunol Rev (2017) 0.76
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. PLoS One (2017) 0.76
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. J Infect Dis (2016) 0.75
Infection of rhesus macaques with a pool of simian immunodeficiency virus with the envelope genes from acute HIV-1 infections. AIDS Res Ther (2016) 0.75
Fcgbp - A Potential Viral Trap in RV144. Open AIDS J (2014) 0.75
Utilizing a TLR5-Adjuvanted Cytomegalovirus as a Lentiviral Vaccine in the Nonhuman Primate Model for AIDS. PLoS One (2016) 0.75
Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. JCI Insight (2016) 0.75
New prospects for a preventive HIV-1 vaccine. J Virus Erad (2015) 0.75
Survivors Remorse: antibody-mediated protection against HIV-1. Immunol Rev (2017) 0.75
Predicting Overall Vaccine Efficacy in a New Setting by Re-Calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy. Epidemiol Method (2016) 0.75
Imaging and tracking HIV viruses in human cervical mucus. J Biomed Opt (2016) 0.75
First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses. Retrovirology (2016) 0.75
Comprehensive Characterization of Reference Standard Lots of HIV-1 Subtype C Gp120 Proteins for Clinical Trials in Southern African Regions. Vaccines (Basel) (2016) 0.75
An HIV envelope gp120-Fc fusion protein elicits effector antibody responses in rhesus macaques. Clin Vaccine Immunol (2017) 0.75
Lessons learned from human HIV vaccine trials. Curr Opin HIV AIDS (2017) 0.75
Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand. PLoS One (2015) 0.75
Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. Cell (2017) 0.75
Quantitative analyses reveal distinct sensitivities of the capture of HIV-1 primary viruses and pseudoviruses to broadly neutralizing antibodies. Virology (2017) 0.75
A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. Front Immunol (2017) 0.75
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol (2010) 7.72
Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis (2009) 6.96
Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis (2008) 5.69
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature (2012) 5.49
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med (2008) 3.35
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med (2011) 3.08
Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol (2010) 2.67
Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol (2010) 2.39
Immunology and the elusive AIDS vaccine. Nature (2010) 2.26
Simultaneous inferences on the contrast of two hazard functions with censored observations. Biometrics (2002) 2.18
T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol (2009) 2.17
Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr (2005) 1.68
Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge. J Virol (2010) 1.66
HIV/AIDS prevention in Thailand: success and challenges. Science (1998) 1.54
Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect Dis (2004) 1.46
UK Guideline for the use of post-exposure prophylaxis for HIV following sexual exposure. Int J STD AIDS (2006) 1.46
Roadblocks in HIV research: five questions. Nat Med (2009) 1.33
Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis (2004) 1.20
Estimation of "needs" and "probable uptake" for HIV/AIDS preventive vaccines based on possible policies and likely acceptance (a WHO/UNAIDS/IAVI study). Vaccine (2003) 1.12
Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand. Jpn J Infect Dis (2006) 1.01
Viral phenotype and CCR5 genotype. Nat Med (1999) 0.85
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98
Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr (2003) 7.23
The burden of selected digestive diseases in the United States. Gastroenterology (2002) 6.79
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature (2012) 5.49
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med (2005) 4.65
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol (2005) 4.35
Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med (2008) 4.21
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature (2012) 3.83
Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One (2012) 3.69
Induction of foxP3+ regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol (2004) 3.62
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis (2012) 3.42
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
Bacterial coaggregation: an integral process in the development of multi-species biofilms. Trends Microbiol (2003) 3.17
Host determinants of HIV-1 control in African Americans. J Infect Dis (2010) 2.90
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 2.74
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A (2013) 2.69
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47
Stage-dependent production and release of histidine-rich protein 2 by Plasmodium falciparum. Trans R Soc Trop Med Hyg (2005) 2.38
Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology (2008) 2.37
Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med (2014) 2.27
Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci U S A (2009) 2.22
Prospective population-based incidence of Haemophilus influenzae type b meningitis in Thailand. Vaccine (2004) 2.18
Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci U S A (2003) 2.14
Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol (2004) 2.13
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci U S A (2005) 2.10
Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis (2004) 2.01
Intertester reliability of the acceptable noise level. J Am Acad Audiol (2012) 2.00
Reference ranges for the clinical laboratory derived from a rural population in Kericho, Kenya. PLoS One (2008) 1.97
Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine (2005) 1.96
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94